Physician profile
Sherman Chamberlain
NPI 1104936855
$3,825.17
in general payments reported to CMS, 2019-2025
34 companies · $750 in 2025
The $750 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $268 · 2020: $18.17 · 2021: $398 · 2022: $1,322 · 2023: $536 · 2024: $534 · 2025: $750.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,741 · Education: $79.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,740.81 |
| Education | $79.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $614.84 | 2021-2025 | Tremfya, Stelara, Remicade |
| Abbvie INC. | $610.55 | 2019-2025 | Rinvoq, Viberzi, Linzess |
| Celgene Corporation | $351.70 | 2021-2024 | Zeposia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $291.31 | 2021-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $230.72 | 2021-2025 | Entyvio |
| Merck Sharp & Dohme LLC | $227.45 | 2021-2024 | Dificid |
| Pfizer INC. | $166.64 | 2023-2025 | |
| Medtronic, INC. | $162.24 | 2022 | |
| Ardelyx, INC. | $130.17 | 2022-2025 | Ibsrela |
| E.R. Squibb & Sons, L.L.C. | $125.00 | 2022 | |
| Intercept Pharmaceuticals, INC. | $94.13 | 2019-2022 | |
| Gilead Sciences, INC. | $86.28 | 2021-2025 | |
| Novo Nordisk INC | $67.90 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $54.93 | 2022-2025 | Sutab, Suflave |
| Cumberland Pharmaceuticals, INC. | $54.02 | 2023 | Kristalose |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $46.77 | 2024-2025 | Rezdiffra, Resmetirom |
| Boston Scientific Corporation | $46.03 | 2019-2021 | |
| Lilly USA, LLC | $41.10 | 2023-2025 | Omvoh |
| Pacira Pharmaceuticals Incorporated | $40.22 | 2025 | Zilretta, Iovera |
| Phathom Pharmaceuticals, INC. | $39.69 | 2024 | Voquezna |
| Olympus America INC. | $38.48 | 2025 | Endoclot Phs, Single Use Electrosurgical Hemostatic Forceps, Disposable Biopsy Forceps |
| Ironwood Pharmaceuticals, INC | $37.21 | 2019-2025 | |
| Allergan, INC. | $37.14 | 2019 | |
| Nestle Healthcare Nutrition INC. | $34.49 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $27.22 | 2022 | |
| Redhill Biopharma INC. | $24.01 | 2021 | |
| Intuitive Surgical, INC. | $23.83 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.25 | 2019 | |
| Vivus LLC | $18.39 | 2024 | Pancreaze |
| Avanir Pharmaceuticals, INC. | $18.39 | 2019 | |
| Janssen Pharmaceuticals, INC | $18.03 | 2019 | |
| Aimmune Therapeutics, INC. | $15.66 | 2024 | |
| Evoke Pharma, INC. | $15.39 | 2023 | Gimoti |
| Micro-Tech Endoscopy USA, INC. | $14.99 | 2023 | Sureclip |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sherman Chamberlain listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.